Global Biosimilars Market Research Report 2020 Analysis and Forecast to 2025

  Biosimilars Market Scenario

Biosimilars Market Growth is expected to register a CAGR of 7.5% during the forecast period of 2019 to 2025, with a market value of USD 13,460 Million in 2018.

A biosimilar is a biologic medical product highly similar to another already approved biological medicine. Biosimilars are approved according to the same standards of pharmaceutical quality, safety, and efficacy that apply to all biological medicines. The global biosimilars market is driven by factors such as rising demand for biosimilars due to their cost-effectiveness and growing prevalence of chronic diseases. Additionally, rising pressure to reduce healthcare expenditure coupled with patent expiry of various blockbuster drugs and the increasing number of biosimilar drug approvals by the FDA is anticipated to fuel the market growth.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/1329 

For instance, according to the biosimilars update report by Amgen in 2019, As of January 2019, the US Food and Drug Administration (FDA) approved 17 biosimilars, out of which 7 products launched in 4 therapeutic areas. On the other hand, patient safety and medical efficacy are projected to hamper the growth of the market during the assessment period. Moreover, major companies in the market are involved in strategic acquisitions, collaborations, and mergers to sustain their position in the market.

For instance, in October 2018, Sandoz, a Novartis division received the US Food and Drug Administration (FDA) approval for its biosimilar, HyrimozTM (adalimumab-adaz) for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PSA),  juvenile idiopathic arthritis (JIA) in patients four years of age and older, ulcerative colitis (UC), ankylosing spondylitis (AS), adult Crohn's disease (CD), and plaque psoriasis (Ps)

Biosimilars Market Segmentation

Global Biosimilars Market has been segmented based on product, applications, end users, and region.

The market, based on product, has been bifurcated into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides.

The recombinant non-glycosylated proteins are further divided into human growth hormone (RHGH), granulocyte colony-stimulating factor (filgrastim), insulin, and interferons. Similarly, the recombinant glycosylated proteins segment is further bifurcated into erythropoietin (EPO), monoclonal antibodies (MABS), and follitropin. The recombinant peptides segment has been subdivided into glucagon and calcitonin

The recombinant non-glycosylated proteins segment is expected to hold a major share in the market due to an increase in the number of incidences of chronic diseases, diabetes also growth hormone deficiency-related disorders. Thus, the therapeutic use of recombinant non-glycosylated proteins is broadening as their increased availability and lowered price.  

For example, according to the International Diabetes Federation (IDF), in 2017, approximately 425 million adults aged between 20 to 79 years suffered from diabetes, and this number is expected to rise to 629 million by 2045.

On the basis of applications, the global biosimilars market has been divided into oncology, chronic diseases, autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases, and others. Blood disorders segment is expected to grow with high growth rate due to increased prevalence of blood disorders and adoption of biosimilars as its low cost in comparison to biologics reduces the treatment cost.

For example, according to the Centers for Disease Control and Prevention in the US, hemophilia A affects 1 in 5,000 male births, and about 400 babies are born with hemophilia A each year.

Based on end user, the market has been divided into hospitals and clinics is expected to hold the largest share in the market as easy availability for treatment with expert faculties.

Based on region, the global biosimilars market has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The biosimilars market in the Americas has further been segmented into North America and Latin America; the North American market has been further divided into the US and Canada.

The European biosimilars market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified as France, the UK, Germany, Italy, Spain, and the rest of Western Europe. The biosimilars market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The biosimilars market in the Middle East & Africa has been divided into the Middle East and Africa.

Biosimilars Market Key Players

The key players in the Global Biosimilars Market are Pfizer (US), Sandoz International (Germany), Teva Pharmaceuticals (Israel), Amgen, Inc. (US), Biocon (India), Dr. Reddy’s Laboratories (India), Celltrion (South Korea), Samsung Biologics (South Korea), Eli Lily & Company (US), Hospira Inc.(US), Actavis, Inc.(US), Cipla Ltd (India), Stada Arzneimittel AG (Germany), and Mylan, Inc.(US).

Regional Market Summary

The market in Europe is expected to dominate the global biosimilars market due to the increasing biosimilar product approvals and the emergence of new market participants in the region. The growing prevalence of chronic diseases in the US and Canada is expected to drive the market growth. Furthermore, there has been an increase in the expenditure in research by healthcare bodies; this is expected to fuel the growth of the market in this region. For example, according to Amgen, in 2019, Europe has an advanced biosimilar market, with 53 approved biosimilar products. The market in Asia-Pacific expected to show a considerable amount of growth. This can be attributed to the patent expiry of biologic products, introduction of new biosimilars, adoption of biosimilars to reduce the treatment cost, and the involvement of key companies. For instance, according to the National Center for Biotechnology Information, in 2019, Many key biologics are scheduled to lose their patent by the year 2020, which will provide the opportunity to other biopharmaceutical companies to develop similar biologics. Already there are more than 100 Indian biopharmaceutical companies are engaged in manufacturing and marketing of biosimilar. The market in Americas is projected to have a steady growth rate during the forecast period owing to an increase in chronic diseases and well-developed healthcare system. The market in the Middle East & Africa is projected to account for the least share of the global market due to low disposable income in the region.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/biosimilars-market-1329 

 

Erectile Dysfunction Drugs Market to Witness Widespread Expansion During 2020 to 2023

  Erectile Dysfunction Drugs Market Overview: 

The global market for erectile dysfunction drugs market is set to cross a valuation of USD 2930million by 2023 with a CAGR of 3.5% during the forecast period (2018-2023). Market Research Future revealed several factors like a rising recording of cases of erectile disorder, increasing geriatric population, expiry of patents of major blockbuster drugs, and better drug development as major reasons behind the growth of the erectile dysfunction drugs market. Growth in the sedentary lifestyle may also boost the demand for such drugs.  

However, patients often fail to adhere to these drugs in proper terms, which can restrain the growth of this erectile dysfunction drug market demand.  

Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @ https://www.marketresearchfuture.com/sample_request/1313

Erectile Dysfunction Drugs Market Segmentation: 

The global erectile dysfunction drugs market, on account of MRFR experts, has been segmented based on drugs and end users. This segmentation is expected to reveal insight related to dynamics, growth factors, and demographic challenges. These insights will be further backed by figures received after detailed analysis.  

By drug, the global market on the erectile dysfunction drugs has been segmented into Cialis (tadalafil), staxyn/Levitra (vardenafil), viagra (sildenafil citrate), zydena (udenafil), vitaros (alprostadil cream), stendra/spedra (avanafil), and others. Viagra has a huge market share as it is the first-of-its-kind drug that received the approval of the FDA in 1998. Cialis is expected to make a better impact on the market in terms of growth as its erection period is higher than that of Viagra.  

By end user, the global market for erectile dysfunction drugs has been segmented into retail pharmacy, hospital pharmacy, and online pharmacy. The retail pharmacy segment is expected to benefit from the easy availability of drugs. The segment is the largest one. Hospitals are expected to gain more from growing awareness and are expected to be the fastest one in terms of growth.  

Erectile Dysfunction Drugs Market Regional Analysis: 

The Americas are set to dominate the global erectile dysfunction drugs market. This is primarily due to the rising presence of major drug companies and the increasing adoption of various new technologies to treat the disorder. Also, the growing awareness regarding the disorder is expected to boost the market profit. In Asia Pacific, rising awareness and the massive population are expected to play in favor of the market.  

Erectile Dysfunction Drugs Market Competitive Landscape: 

Global erectile dysfunction drugs market is expected to get boosted by the strategic developments launched by companies like Apricus Biosciences Inc., Bayer AG, Pfizer, Inc., Dong-A Pharmaceutical Co. Ltd., Cristalia Produtos Quimicos Farmaceuticos Ltd., Meda Pharmaceuticals, Inc., Eli Lilly and Company, Vivus, Inc., S.K. Chemicals Co. Ltd., Teva Pharmaceutical Industries Ltd., and others. These companies are showing an intent to take the global market forward by constantly indulging in various strategic discussions where they are working on mergers, acquisitions, collaborations, hike in investment for research and development, branding strategies, distribution channels, and others. MRFR’s recording of all the latest proceedings is expected to improve the scope of market study.  

Industry News: 

In May 2020, a report revealed that the global market for erectile dysfunction drugs market had witnessed a price fall in both generic and branded drugs between July 2019 and January 2020. But the price of branded drugs has bounced back after February 2020. The report is on the basis of a close analysis of several online drug supply chain. One of the major reasons behind this price change is COVID-19. The rise in home delivery services has changed the market expectations and the price is getting impacted by that.

Browse Complete Report @ https://www.marketresearchfuture.com/reports/erectile-dysfunction-drugs-market-1313  

Future Growth of Preclinical Imaging Market is Expected to Grow Healthy CAGR till 2023

 

Market Highlights

The global preclinical imaging anticipated to have held a market value of USD 2.01 billion in the year 2017 and is expected to grow at a CAGR of 6.3% during the forecast period. Preclinical imaging solutions are used during the preclinical research for visualization of living animals. It is playing important role during drug development process. It is evaluating the effectiveness and safety of new treatments and describing drug distribution patterns before clinical use. preclinical imaging solutions has broad application field such as, neurology; cardiology; inflammation; infectious diseases; cancer research; functional and anatomical neuroimaging, orthopedics; and cardiac imaging.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/7365 

Technological advancements in the field of molecular imaging, increasing market demand for non-invasive small-animal imaging techniques, and increasing funding to support preclinical researches are expected to drive the growth of preclinical imaging market. Many organization and foundation provide the funding support for the preclinical researche activity. The Alzheimer's Drug Discovery Foundation was providing the funding opportunity for preclinical study up to USD 5 million. Similarly, in 2015 Deutsches Zentrum für Herz-Kreislaufforschung e.V. (DZHK) offered Euro 6 million for the preclinical research projects. This funding supports the market growth.

Regional Analysis

Geographically, the Americas is expected to dominate the global preclinical imaging market owing to the presence of well-established players, technological advancements in the field of molecular imaging, increasing market demand for non-invasive small-animal imaging techniques, and increasing funding to support preclinical researches. Europe is expected to hold the second largest position in the global preclinical imaging market. Asia-Pacific is expected to be the fastest growing market owing to the increasing funding to support preclinical researches. Furthermore, the Middle East and Africa region is expected to account for the least market share in the global preclinical imaging market.

Segmentation

The global preclinical imaging market has been segmented into modality, reagent, and region.

Based on modality, preclinical imaging market is segmented into optical imaging systems, nuclear imaging systems, micro-MRI, micro-ultrasound, micro-CT, photoacoustic imaging system, and magnetic particle imaging systems. The optical imaging systems segment is expected to account for the largest share segment of the market in 2017.

Based on reagent, preclinical imaging market is segmented into preclinical optical imaging reagents, preclinical nuclear imaging reagents, preclinical MRI contrast agents, preclinical ultrasound contrast agents, and preclinical CT contrast agents. The preclinical optical imaging reagents segment is expected to account for the largest share segment of the market in 2017.

Key Players

Some of the prominent players in the global preclinical imaging market are Bruker Corporation (US), MR Solutions (UK), PerkinElmer Inc. (US), Fujifilm Holdings Corporation (Japan), Milabs B.V. (The Netherlands), Mediso Ltd. (Hungary), LI-COR, Inc. (US), Miltenyi Biotec GmbH (Germany), Aspect Imaging (Israel), and Trifoil Imaging (US).

Browse Complete Report @ https://www.marketresearchfuture.com/reports/preclinical-imaging-market-7365 

Veterinary Laboratory Testing Market to Witness Widespread Expansion During 2020 to 2023

 

Market Highlights

The global veterinary laboratory testing market is expected to grow at a CAGR of 10.1% during the forecast period.

Increasing expenditure on pet insurance, growth in the number of veterinary practitioners, advancements in healthcare facilities, and favorable funding policies are expected to drive the market growth over the forecast period.

However, high cost of veterinary testing and complications associated with the tests can restrain the market growth over the assessment period.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/7326   

Regional Analysis

Geographically, the Americas is anticipated to dominate the global veterinary laboratory testing market owing to the increasing cases of animal disease and technological advancements in veterinary diagnostics. For instance, in 2016, IDEXX Laboratories, Inc. launched the Rapid Visual Pregnancy Test for cattle. With the new test, veterinarians can more quickly identify open cows using whole blood samples collected before the farm visit. Europe is expected to hold the second largest position in the global veterinary laboratory testing market. The market growth in this region is attributed to the rising expenditure on pet insurance. The Veterinary Laboratory Testing Market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the awareness regarding use of sterile consumables for lab testing and rising healthcare spending. The Middle East & Africa contributes least in the global market for veterinary laboratory testing.\

Segmentation

The global veterinary laboratory testing market has been segmented into animal type, technology, product, and end user.

The market, on the basis of animal type, has been segmented into companion animal and livestock animal. The companion animal segment is further classified as dogs, cats, horses and others. The livestock animal segment is further classified as cattle, pigs, poultry and others.

The market, by technology, has been segmented into clinical biochemistry, immunodiagnostics, hematology, molecular diagnostics, urinalysis, and others.

The clinical biochemistry segment is further classified as clinical chemistry analysis, glucose monitoring, and blood gas & electrolyte analysis. The clinical chemistry analysis segment includes clinical chemistry reagent clips and cartridges and clinical chemistry analyzers. The glucose monitoring segment includes blood glucose strips, glucose monitors and urine glucose strips. The blood gas & electrolyte analysis segment includes blood gas and electrolyte reagent clips and cartridges and blood gas & electrolyte analyzers.

The immunodiagnostics segment is further classified as ELISA tests, lateral flow assays, allergen-specific immunodiagnostic tests, immunoassay analyzers, and others. The lateral flow assays segment includes lateral flow rapid tests, and lateral flow strip readers.

The hematology segment is further classified as hematology cartridges, and hematology analyzers.

The molecular diagnostics segment is further classified as polymerase chain reaction (PCR) tests, microarrays, and others.

The urinalysis segment is further classified as urinalysis clips & cartridges/panels, urine analyzers, and urine test strips.

The market, by product, has been segmented into consumables and instruments.

The market, by end user, has been segmented into veterinary hospitals & clinics, in-house testing, research institutes, diagnostic laboratories, and others. The veterinary hospitals & clinics segment held the largest segment of the market in 2017. This can be attributed to the increasing incidence of zoonotic diseases. On the other hand, the academic institutes segment is estimated to be the fastest growing segment.

Key Players

Some of the prominent players in the global veterinary laboratory testing market are Abaxis, Inc., BIOCHECK Inc., Biomérieux SA, Henry Schein, Inc., Heska Corporation, Idexx Laboratories, Idvet, Neogen Corporation, Pfizer, Qiagen N.V., Randox Laboratories, Ltd., Thermo Fisher Scientific, VCA Inc., Virbac, Zoetis, Inc. and others.

Browse Complete Report @ https://www.marketresearchfuture.com/reports/veterinary-laboratory-testing-market-7326 

Global Single-Photon Emission Computed Tomography (SPECT) Market Research Report 2020 Analysis and Forecast to 2023

 

Market Highlights

The growing acceptance of Single-Photon Emission Computed Tomography (SPECT) accustomed by its technical advances is one of the major trends witnessed in the global SPECT market over the forecast period. Imaging devices are becoming more advanced, efficient, and evolved in terms of technology. The SPECT scanner has two integral parts namely computed tomography (CT) and a radioactive material (tracer). Basically, these tracers are used to diagnose and predict outcomes in various disease states by monitoring the therapeutic effects.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/7231 

The Single-Photon Emission Computed Tomography (SPECT) market is expected to witness tremendous growth owing to the new 99mtc labelled agents for visualizing biologically significant events, and integration of X-ray tomography (CT) In SPECT. Other key factors such significant investments in R&D and expansions undertaken by key players are contributing towards the growth of the market. However, challenges such as need for skilled professionals, and reimbursement issues, is likely to curb the market growth during the forecast period.

Segmentation

The global Single-Photon Emission Computed Tomography (SPECT) market is segmented into type, application, end-users. The Single-Photon Emission Computed Tomography (SPECT) market, by type, the market is segmented into hybrid SPECT systems, and standalone SPECT systems. On the basis of application, the Single-Photon Emission Computed Tomography (SPECT) market is bifurcated into oncology, cardiology, neurology, and others. On the basis of end-user, the market is segmented into hospitals, diagnostic imaging centers, academic & research centers, and others.

Regional Analysis

The Americas is the largest in the market owing to the improving research infrastructure in the region, coupled with the rising awareness among patients and physicians for radioisotopes. Further, SPECT has reportedly been combined with CT and MRI to provide detailed anatomical and metabolic information. It is currently exhibiting a highly lucrative growth rate due to an increased use of SPECT for diagnosis of cardiac diseases, brain diseases, etc.

The European region is the second largest SPECT market over the forecast period due to high acceptance of SPECT in research & development along with the rising incidence of chronic disease like cancers are also accountable for the growth of the Single-Photon Emission Computed Tomography (SPECT) market. 

The Asia Pacific region is likely to develop at the uppermost CAGR for the Single-Photon Emission Computed Tomography (SPECT) market in the years to come. Moreover, the rising diagnostic care services both at the hospitals and at community level are expected to influence the market in a positive way. The Middle East and Africa accounts for the least market share due to low per capita income and lack of availability of well-trained healthcare professionals.

Key Players

Some of the key players in the global Single-Photon Emission Computed Tomography (SPECT) market are GE Healthcare, Siemens Healthcare, Koninklijke Philips N.V., Bruker Corporation, Mediso Ltd., Digirad Corporation, Spectrum Dynamics Medical, DDD-Diagnostic A/S, MiE America, Inc., CardiArc, Beijing Hamamatsu Photon Techniques INC., SHENZHEN BASDA MEDICAL APPARATUS CO., LTD.

PNPMedM, NuCare Inc., and others.

Browse Complete Report @ https://www.marketresearchfuture.com/reports/single-photon-emission-computed-tomography-market-7231

Detail Study on Chronic Lymphocytic Leukemia Treatment Market is Projected to Grow Magnificent CAGR till 2023

 Market Scenario

As per the data experts at Market Research Future (MRFR), the chronic lymphocytic leukemia treatment market was worth USD 7.9 Billion in 2017. Additionally, the market is expected to expand at a growth rate of 19% over the forecast period (2018-2023).

Market Drivers and Key Challenges

Chronic lymphocytic leukemia is considered to be one of the most common types of leukemia in adults. This type of cancer involves the development of lymphocytes, which are white blood cells, within the bone marrow. The lymphocytic leukemia cells are generally present in the lymph nodes along with various other tissues. There are two primary types of chronic lymphocytic leukemia, wherein one grows slowly, and the other is considered fatal. In general, one does not experience any symptoms due to chronic lymphocytic leukemia for a long period. However, the symptoms usually noted include fatigue, easy bruising, and swollen lymph nodes.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6900 

Generally, the most popular form of treatment for CLL is chemotherapy, whereas stem-cell transplant is for rare cases. An article published by Apollo Hospitals states that in India, roughly one million cases of chronic lymphocytic leukemia are diagnosed annually. As per the cancer statistics, 1 in every 155 men and 1 in every 260 women get affected with CLL in their lifetime, in the United Kingdom (U.K). The boost in cancer cases around the world, innovations in drug therapy, quick regulatory approval processes, and vigorous pipeline of drugs for chronic lymphocytic leukemia treatment are additional factors substantiating the growth of the chronic lymphocytic leukemia market.

Having said that, the stunted level of awareness with regard to symptoms is expected to retard the market growth in the forthcoming years. However, growing research & development activities coupled with continuous technological developments in the field is presumed to augment the market growth to a large extent.

Market Segmentation

The global chronic lymphocytic leukemia treatment market has been segmented on the basis of type, treatment, and end user.

The market, in terms of the type, has been considered for indolent CLL and aggressive CLL.

The market, treatment-wise, can be broken down into chemotherapy, targeted drug therapy, immunotherapy, and bone marrow transplant.

The end users in the global market are hospitals & clinics, diagnostic laboratories, research institutes, and others.

Prominent Players

The prominent vendors within the worldwide chronic lymphocytic leukemia treatment market include Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca, Genmab A/S, TG Therapeutics, Inc., Ziopharm Oncology, F. Hoffmann-La Roche Ltd, AbbVie Inc., Genentech, Inc., Gilead, Genzyme Corporation, ONO PHARMACEUTICAL CO., LTD., GlaxoSmithKline plc, CELGENE CORPORATION, Inc., Johnson & Johnson Services, Inc., and others.

Browse Full Report Details @ https://www.marketresearchfuture.com/reports/chronic-lymphocytic-leukemia-treatment-market-6900

 

3D Printing Medical Devices Market to Witness Widespread Expansion During 2020 to 2023

 3D Printing Medical Devices Market Overview

As per Market Research Future (MRFR) analysis, the global 3D printing medical devices market is projected to grow at a CAGR of 18% from 2018 to 2023 (forecast period). 

3D printing plays a vital role in the development of medical and dental devices. 3D printing is the most commonly used medical device and, due to its versatility, can also be used for other items, including food, household items, and automotive parts. The 3D printing technology is used to treat various types of therapies, such as hip and jaw titanium replacements, limb prosthetics and plastic tracheal splints, etc. Due to advanced technology and easy use of devices, many doctors prefer 3D printing devices before surgeries of any organ part that may minimize error. A computer-aided design drawing or a magnetic resonance image is a 3D object created from a digital 3D image. The 3D object is formed by creating successive layers of material in which each layer is connected to the previous layer until the object is complete. Various types of materials are used to create a 3D image. 

Get a FREE Sample with Complete TOC @ https://www.marketresearchfuture.com/sample_request/6830

3D Printing Medical Devices Market Dynamics 

The global market for 3D printing medical devices is expected to expand due to growing government spending in the healthcare sector, rising technological developments in 3D printing, easy production of medical devices, and the growing use of 3D printing devices in the healthcare sector. 3D printing plays a crucial role in the medical and dental manufacturing market. This is a very cost-effective and preferred choice for medical device manufacturers for all kinds of medical devices such as prostheses, hearing aids, custom knee, and hip implants. The 3D printing medical devices are expected to show substantial growth during the forecast period due to various technological developments in this field. In addition, a variety of other factors, such as investment in R&D, rapidly growing consumer base, increasing the reach of biomedical applications, have driven market growth. 

However, some aspects that may hinder future market growth are unfavorable reimbursement policies, high printer costs, biocompatibility issues for 3D printed medical devices, and limited technical knowledge in medical devices. 

3D Printing Medical Devices Market Segmentation 

The global market for 3D printing medical devices has been segmented into types, components, technology, application, and end-users. 

Based on types, the global market for 3D printing medical devices is classified into the segments of surgical guides, prosthetics & implants, surgical instruments, and tissue engineering products. The Surgical Guide is predicted to hold the largest share of the 3D printing market for medical devices in the forecast period. The 3D printing surgical guide is part of operation preparation and offers precise restoration of the implant. The demand for a surgical guide is therefore growing which is a significant factor driving the growth of this market segment. 

Based on components, the global market for 3D printing medical devices is divided into materials software & services, 3D printer, and 3D bioprinter. Software & services are projected to register for the largest market share in 3D medical device printing in the forecast period. Growing development of software solutions for the production of high-quality 3D-printed medical products is a primary driver of the growth of the services and software segment. 

On the basis of technology, the market for 3D printing medical device is segmented into 3D printing, droplet deposition, laser beam melting, photopolymerization, laminated object manufacturing (LOM), electron beam melting (EBM), polyjet technology and others. Photopolymerization is projected to maintain the largest market share in the 3D printing medical device.  

Depending on the application, the global 3D printing medical device market is segmented into external wearable devices, implants and tissue engineering, and clinical trial devices. The external wearable devices segment retains the largest share of the 3D printing medical devices market in the forecast period. 

Depending on end-users, the global 3D printing medical device market is categorized into hospitals, medical and surgical centers, pharmaceutical and biotech firms, academic institutions, and contract research organizations. The segment of medical and surgical centers accounts for the largest share of the 3D printing medical devices market due to an increasingly growing patient population and reduced risk of surgery and infection. 

3D Printing Medical Devices Market Regional Analysis 

The market has been segmented by area across the Americas, Europe, the Asia Pacific and the Middle East and Africa. The market for 3D printing medical device in the Americas has been further broken down into North America and South America, with the North American market split into the USA and Canada. The European market for 3D printing medical devices has been segmented into Western Europe and Eastern Europe. Western Europe has also been listed as Germany, France, the United Kingdom, Italy, Spain, and the rest of Western Europe. The market for 3D printing medical devices in the Asia Pacific has been segmented into China, Japan, India, Australia, South Korea, and the rest of the Asia Pacific. The market for biomaterials in the Middle East and Africa has been segmented into the Middle East and Africa. 

North America dominates the market for global 3D printing medical devices over the forecast period. The largest share is due to a growing demand for organ transplantation across the region. Some of the aspects responsible for market growth in this region are attributed to increased government spending to develop advancements in 3D printing technologies and applications. 

The second-largest 3D printing medical devices market is projected to be the European market. Market growth in this region can be ascribed to government funding and support for the healthcare sector, combined with increased research and development. In addition, an increasing number of surgeries due to changing lifestyles are leading to the growth of the market in the region. 

The Asia Pacific is predicted to be the fastest-growing 3D printing medical device market in the forecast period due to the rising prevalence of chronic diseases, increasing investment in healthcare, growing geriatric population, and the proliferation of market players in the region. 

The market in the Middle East and Africa is projected to register for the smallest share of the market for global 3D printing medical devices due to underdeveloped healthcare, lack of technological expertise and inadequate medical facilities. 

3D Printing Medical Devices Market Key Players  

Some of the prominent players in the market for 3D printing medical devices are SLM Solutions Group AG, 3D Systems Corporations, Stratasys Ltd., EnvisionTEC, Arcam AB, Organovo Holdings, Inc., Materialise NV, Oxford Performance Materials, Inc., Bio3D Technologies, Prodways Group, Cyfuse Medical K.K.EOS GmbHConcept, Laser GmbH, 3T RPD Ltd, Renishaw plc.

Obtain Premium Research Report Details @ https://www.marketresearchfuture.com/reports/3d-printing-medical-devices-market-6830